Eating one orange a day could prevent a common cause of blindness
Researchers from the University of Sydney found that snacking on the popular citrus fruit reduces people's risk of developing age-related macular degeneration, which affects central vision. (Source: the Mail online | Health)
Source: the Mail online | Health - July 13, 2018 Category: Consumer Health News Source Type: news

7 medtech stories we missed this week: July 13, 2018
[Image from unsplash.com]From Angiodroid receiving CE Mark approval to Masimo launching its vital signs app, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. Angiodroid wins CE Mark for Angiopulse IABP Angiodroid announced in a July 11 press release that it has received CE Mark approval for its AngioPulse intra-aortic balloon pump device. The AngioPulse uses a new system for intra-aortic balloon pumps based on pressure regulation. It is designed for weaning solutions and is suitable for all types of patients needing intra-aortic balloon pump therapy. 2. Visura Technol...
Source: Mass Device - July 13, 2018 Category: Medical Devices Authors: Danielle Kirsh Tags: 510(k) Diagnostics Food & Drug Administration (FDA) Imaging Patient Monitoring Regulatory/Compliance Surgical Ultrasound angiodroid Healcerio Lipogems Masimo MedTech Oculocare ReDress Visura Technologies Source Type: news

Eating just one orange a day could prevent a common cause of blindness
Researchers from the University of Sydney found that snacking on the popular citrus fruit reduces people's risk of developing age-related macular degeneration, which affects central vision. (Source: the Mail online | Health)
Source: the Mail online | Health - July 13, 2018 Category: Consumer Health News Source Type: news

Cilioretinal Artery May Protect Against AMD (CME/CE)
(MedPage Today) -- Findings could be clue to'wet'age-related macular degeneration etiology (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - July 9, 2018 Category: Primary Care Source Type: news

OptoVue wins FDA nod for AngioAnalytics tech
Ophthalmological-focused developer Optovue said yesterday it won FDA 510(k) clearance for its AngioAnalytics optical coherence tomography angiography blood vessel measurement tech designed to aid in managing disease that cause progressive blindness. The Fremont, Calif.-based company said it also won clearance for its 3D projection artifact removal software, designed to improve OCTA image quality to allow for accurate measurements and interpretation of its OCTA images. OptoVue touted that the newly cleared AngioAnalytics tech adds to its currently released AngioVue OCTA technology designed to provide high-resoluti...
Source: Mass Device - June 12, 2018 Category: Medical Devices Authors: Fink Densford Tags: 510(k) Food & Drug Administration (FDA) Imaging Optical/Ophthalmic Regulatory/Compliance Optovue Source Type: news

More than 20 people go blind a month in the UK due to delayed and cancelled hospital appointments
More than half of the people in the UK suffering from treatable conditions such as wet age-related macular degeneration and glaucoma, have had an appointment postponed or cancelled at least once. (Source: the Mail online | Health)
Source: the Mail online | Health - June 6, 2018 Category: Consumer Health News Source Type: news

Mediterranean Diet Linked With Lower Incidence of Advanced AMD Mediterranean Diet Linked With Lower Incidence of Advanced AMD
People who eat a Mediterranean diet are less likely to develop advanced age-related macular degeneration (AMD).Reuters Health Information (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - June 5, 2018 Category: Opthalmology Tags: Ophthalmology News Source Type: news

Better Outcomes of 2nd Eye With Choroidal Neovascularization After Anti-VEGF Treatment Better Outcomes of 2nd Eye With Choroidal Neovascularization After Anti-VEGF Treatment
Visual acuity outcomes after anti-vascular endothelial growth factor (anti-VEGF) treatment for choroidal neovascularization (CNV) are better in fellow eyes of previously treated patients with neovascular age-related macular degeneration (nvAMD), according to a retrospective study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 16, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Bayer receives approval for Eylea ® in China (for specialized target groups only)
Eylea ® gains approval in China for the treatment of visual impairment due to neovascular (wet) age-related macular degeneration (Source: Bayer Company News)
Source: Bayer Company News - May 11, 2018 Category: Pharmaceuticals Source Type: news

Cochrane Reviews on vision screening and reading aids updated
The College of Optometrists, UK has funded two Cochrane Review updates in support of theCochrane Eyes and Vision (CEV) group based at the London School of Hygiene and Tropical Medicine (LSHTM). The global review updates were used to answer questions on the topics ofVision screening for correctable visual acuity deficits in school-age children and adolescents andReading aids for adults with low vision.The review updates produced the following key findings:Vision screeningThere are no studies comparing vision screening with no vision screening highlighting a gap in evidence.Vision screening with the provision of free spectac...
Source: Cochrane News and Events - April 30, 2018 Category: Information Technology Authors: Muriah Umoquit Source Type: news

After Age 50, Yearly Eye Checks May Catch Common Cause of Vision Loss
SATURDAY, April 28, 2018 -- As the U.S. population ages, vision loss caused by age-related macular degeneration is likely to increase, an ophthalmologist says. Adults over 50 should get an annual test for the condition, said Dr. Ingrid Scott, a... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 28, 2018 Category: General Medicine Source Type: news

Healthy Diet, Healthy Eyes
THURSDAY, April 20, 2018 -- Healthy eating may help preserve your vision as you age, eye experts say. Age-related macular degeneration (AMD) damages the macula (a small area near the center of the retina, located on the inside back layer of the... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 19, 2018 Category: General Medicine Source Type: news

Stem-cell-based Implant Feasible in Macular Degeneration Stem-cell-based Implant Feasible in Macular Degeneration
A bioengineered implant of human embryonic stem-cell-derived retinal pigment epithelium (RPE) may be of benefit in advanced dry age-related macular degeneration (AMD), according to preliminary research.Reuters Health Information (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - April 13, 2018 Category: Transplant Surgery Tags: Ophthalmology News Source Type: news

Stem Cells Show Promise For Macular Degeneration
A new stem cell transplant might help preserve or even restore vision being lost to the dry form of age-related macular degeneration. (Source: WebMD Health)
Source: WebMD Health - April 4, 2018 Category: Consumer Health News Source Type: news

Early Promise for Eye Implant to Fight Macular Degeneration
WEDNESDAY, April 4, 2018 -- A new stem cell transplant might help preserve or even restore vision being lost to the dry form of age-related macular degeneration, a new pilot clinical trial has shown. In the experimental therapy, a specially... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 4, 2018 Category: General Medicine Source Type: news

Treating vision loss
(University of California - Santa Barbara) Age-related macular degeneration (AMD) affects more than 1.75 million individuals in the United States. Because the population is aging, that number will increase to almost 3 million by 2020. Between 80 and 90 percent of cases in this country are the dry version of the condition, for which no effective treatment exists. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 4, 2018 Category: International Medicine & Public Health Source Type: news

Researchers test stem cell-based retinal implant for common cause of vision loss
(University of Southern California - Health Sciences) Physicians and researchers at the USC Roski Eye Institute have collaborated with other California institutions to show that a first-in-kind stem cell-based retinal implant is feasible for use in people with advanced dry age-related macular degeneration. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 4, 2018 Category: International Medicine & Public Health Source Type: news

Treat-Extend-Stop Protocol for Wet AMD: Long-term Outcomes Treat-Extend-Stop Protocol for Wet AMD: Long-term Outcomes
A retrospective study finds that a treat-extend-stop protocol using anti-VEGF agents for neovascular age-related macular degeneration is associated with positive long-term outcomes.Medscape Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 30, 2018 Category: Consumer Health News Tags: Ophthalmology Viewpoint Source Type: news

Early Age-Related Macular Degeneration Linked to High HDL
FRIDAY, March 30, 2018 -- There is a higher risk for early age-related macular degeneration (AMD) in individuals with high plasma high-density lipoprotein cholesterol levels, according to a study published online March 29 in JAMA... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 30, 2018 Category: Pharmaceuticals Source Type: news

Macular Degeneration: Stem Cells Restore Sight in Small Study Macular Degeneration: Stem Cells Restore Sight in Small Study
Doctors in the UK say they have taken an important step towards treating a common form of blindness – wet age-related macular degeneration (AMD).WebMD Health News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 21, 2018 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Stem Cell Transplant Successful in Macular Degeneration Patients: Study
Stem cell therapy restored some vision to two patients with a common cause of blindness called age-related macular degeneration, U.K. doctors say. Stem cells from a human embryo were converted into a patch of a specific type of eye cell and grown... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 20, 2018 Category: General Medicine Source Type: news

Patients regain sight after receiving engineered retinal tissue
The first patients to receive a new treatment derived from stem cells for people with wet age-related macular degeneration have regained reading vision. (Source: Medical Research Council General News)
Source: Medical Research Council General News - March 20, 2018 Category: Research Source Type: news

Doctors hope for blindness cure after restoring patients' sight
Treatment for common cause of blindness could be available within five years, scientists sayA treatment for the commonest cause of blindness could be available within five years, scientists believe, after revealing the first two patients given a revolutionary stem cell therapy have regained enough vision to be able to read.The two patients have advanced AMD – age-related macular degeneration – which destroys the central vision. Both were losing their sight. They were, said their surgeon, unable to see a book, let alone the printed letters.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - March 19, 2018 Category: Science Authors: Sarah Boseley Health editor Tags: Blindness and visual impairment Health Society Disability Science Source Type: news

Retinal patch with stem cells treats macular degeneraiton
Researchers in California have developed a retinal patch with stem cells to improve the vision of people with age-related macular degeneration. (Source: Health News - UPI.com)
Source: Health News - UPI.com - March 19, 2018 Category: Consumer Health News Source Type: news

University College London scientists find possible blindness cure
The groundbreaking trial, conducted at Moorfields Eye Hospital, offers hope of a cure for age-related macular degeneration, which strikes 600,000 adults in the UK. (Source: the Mail online | Health)
Source: the Mail online | Health - March 19, 2018 Category: Consumer Health News Source Type: news

Could THIS be a cure for blindness?
The groundbreaking trial, conducted at Moorfields Eye Hospital, offers hope of a cure for age-related macular degeneration, which strikes 600,000 adults in the UK. (Source: the Mail online | Health)
Source: the Mail online | Health - March 19, 2018 Category: Consumer Health News Source Type: news

Stem cells treat macular degeneration
In July 2015, 86-year-old Douglas Waters developed severe age-related macular degeneration (AMD). He struggled to see things clearly, even when up close. A few months later, he became part of a clinical trial that used stem cell-derived ocular cells developed in part by researchers at UC Santa Barbara. His retinal eyepatch was implanted at Moorfields Eye Hospital, a National Health Service (NHS) facility in Waters' hometown of London, England. (Source: World Pharma News)
Source: World Pharma News - March 19, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Ranibizumab Safe, Effective for Macular Edema Due to Uncommon Causes Ranibizumab Safe, Effective for Macular Edema Due to Uncommon Causes
Ranibizumab 0.5 mg is safe and effective for patients with macular edema (ME) that is not due to diabetes, retinal vein occlusion (RVO) or neovascular age-related macular degeneration (nAMD), according to findings from the PROMETHEUS randomized trial.Reuters Health Information (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - February 28, 2018 Category: Opthalmology Tags: Ophthalmology News Source Type: news

Sex hormone differences affect eye health
According to a study, published in theJournal of Cellular Physiology, gender-based fluctuations in sex hormone levels may directly affect eye physiology, and the progression of age-related macular degeneration.News Medical (Source: Society for Endocrinology)
Source: Society for Endocrinology - January 29, 2018 Category: Endocrinology Source Type: news

Pixium Vision touts 1st use of Prima bionic vision system
Pixium Vision (EPA:PIX) yesterday announced the first successful trial implantation and activation of its Prima next-generation miniaturized wireless photovoltaic sub-retinal implant, and that the system successfully produced visual perception. With the implantation complete, the patient will begin the re-education phase of the study which includes a six-month and 36-month follow-up, the Paris-based company said. “This first successful activation is a major milestone, validating Prima’s concept in patients with advanced dry AMD. The close collaboration between our team at Stanford University and Pixium Vis...
Source: Mass Device - January 26, 2018 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Optical/Ophthalmic Pixium Vision Source Type: news

Innovation Lab eyes local professor as first incubator tenant
The University of Tennessee Health Science Center (UTHSC) has selected a local ophthalmology professor as the first user of its new Innovation Lab. Monica M. Jablonski, who works in UTHSC's College of Medicine, is developing a topical mixture that works better than standard eye drops and is working to improve treatments for conditions such as glaucoma and age-related macular degeneration. Jablonski and her company, OculoTherapy LLC, will ha ve access to the 420-square-foot space within the Memphis… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 24, 2018 Category: Pharmaceuticals Authors: Elle Perry Source Type: news

Innovation Lab eyes local professor as first incubator tenant
The University of Tennessee Health Science Center (UTHSC) has selected a local ophthalmology professor as the first user of its new Innovation Lab. Monica M. Jablonski, who works in UTHSC's College of Medicine, is developing a topical mixture that works better than standard eye drops and is working to improve treatments for conditions such as glaucoma and age-related macular degeneration. Jablonski and her company, OculoTherapy LLC, will ha ve access to the 420-square-foot space within the Memphis… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 24, 2018 Category: Biotechnology Authors: Elle Perry Source Type: news

Is Age-Related Macular Degeneration Declining? Is Age-Related Macular Degeneration Declining?
An aging population should mean an uptick in age-related macular degeneration cases, but recent data suggest that is not what's happening.Medscape Ophthalmology (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - January 18, 2018 Category: Opthalmology Tags: Ophthalmology Commentary Source Type: news

Vitamins for Age-Related Macular Degeneration Vitamins for Age-Related Macular Degeneration
A look at the evidence supporting vitamin therapy for the most common cause of vision loss in US adults: age-related macular degeneration.Medscape Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 16, 2018 Category: Consumer Health News Tags: Ophthalmology Commentary Source Type: news

Ohr Pharmaceutical shares plummet after eye drug fails in wet-AMD trial
Shares in Ohr Pharmaceutical (NSDQ:OHRP) dropped -83% to trade at 35¢ apiece this morning after the company revealed that its topical therapy did not meet the primary endpoint of a trial evaluating its efficacy as a treatment for wet age-related macular degeneration. The company’s Mako study randomized patients 1:1 to receive either Ohr’s topical, twice-daily squalamine therapy in combination with monthly Lucentis injections or a placebo combined with Lucentis. Get the full story at our sister site, Drug Delivery Business News. The post Ohr Pharmaceutical shares plummet after eye drug fails in we...
Source: Mass Device - January 5, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Optical/Ophthalmic Pharmaceuticals Wall Street Beat ohrpharmaceutical Source Type: news

Pixium Vision wins FDA nod for Prima sub-retinal implant study
Pixium Vision (EPA:PIX) said today it won FDA approval to launch a clinical feasibility trial of its Prima next-gen miniaturized wireless photovoltaic sub-retinal implant designed to treat patients with atrophic dry age-related macular degeneration. The trial of the device, which is slated to be conducted at the University of Pittsburgh Medical Center, aims ot recruit 5 patients with vision loss due to atrophic dry age-related macular degeneration, the Paris-based company said. The study’s primary endpoint will be the restoration of visual perception and safety at 12-months, with a longer-term follow up at ...
Source: Mass Device - January 4, 2018 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Food & Drug Administration (FDA) Optical/Ophthalmic Pixium Vision Source Type: news

Mylan, Momenta take aim at Regeneron ’ s Eylea with biosimilar
Momenta Pharmaceuticals (NSDQ:MNTA) and Mylan (NSDQ:MYL) announced yesterday that they plan to launch a pivotal trial in the first half of 2018 for a proposed biosimilar to Regeneron‘s (NSDQ:REGN) blockbuster drug, Eylea. Eylea, a VEGF-inhibitor designed to treat wet age-related macular degeneration and diabetic macular edema, has little competition on today’s market. The drug brought in more than $5 billion for Regeneron in 2016. Get the full story at our sister site, Drug Delivery Business News. The post Mylan, Momenta take aim at Regeneron’s Eylea with biosimilar appeared first on M...
Source: Mass Device - January 4, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Optical/Ophthalmic Pharmaceuticals Wall Street Beat momentapharmaceuticals Mylan Regeneron Source Type: news

A New Form of This Miracle Nutrient Is 8 Times More Powerful …
CoQ10 has made the mainstream. You can find it everywhere. But the type of CoQ10 I want to tell you about has been completely ignored. That’s too bad, because this new form is 8 times better at getting into your blood and staying there. And that’s where it has its miracle-like anti-aging effects. This new form of CoQ10 may give you the opportunity to live disease-free for the rest of your life. Today, I’ll show you how this new “reduced” form of CoQ10 gives you greater power to prevent and reverse disease. You’ll also discover that it ramps up your energy levels and slows your aging proc...
Source: Al Sears, MD Natural Remedies - January 3, 2018 Category: Complementary Medicine Authors: Francisco Cabrera Tags: Nutrition antioxidants CoQ10 ubiquinol Source Type: news

NIH discovery brings stem cell therapy for eye disease closer to the clinic
(NIH/National Eye Institute) Scientists at the National Eye Institute report that tiny tube-like protrusions called primary cilia on cells of the retinal pigment epithelium (RPE) -- a layer of cells in the back of the eye -- are essential for the survival of the retina's light-sensing photoreceptors. The discovery has advanced efforts to make stem cell-derived RPE for transplantation into patients with geographic atrophy, otherwise known as dry age-related macular degeneration (AMD), a leading cause of blindness in the US. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - January 2, 2018 Category: Biology Source Type: news

A drug to treat retinal diseases with drops instead of injections
(FECYT - Spanish Foundation for Science and Technology) The Spanish firm Sylentis has developed a compound to treat diseases of the retina, such as age-related macular degeneration and diabetic retinopathy, which will be administered by ophthalmic drops instead of intraocular injections. The drug, which has been tested in animals, is a small interfering RNA capable of penetrating the cells of the retina and blocking the formation of new blood vessels. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - December 12, 2017 Category: International Medicine & Public Health Source Type: news

At-home vision monitoring app may improve patient care
(American Academy of Ophthalmology) Patients with age-related macular degeneration or diabetic retinopathy who used a mobile application to test their vision at home got comparable results to in-office vision testing, according to research presented today at AAO 2017, the 121st Annual Meeting of the American Academy of Ophthalmology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 13, 2017 Category: International Medicine & Public Health Source Type: news

LumiThera touts interim data from pilot study of LT-300 AMD treatment
LumiThera today announced topline interim results from the Lightsite 1 trial of its LT-300 photobiomodulation device designed to treat dry age-related macular degeneration, touting statistically significant vision benefits maintained to 3 months. Data came from the 30-patient pilot study of the device, funded by a Small Business Innovation Research grant from the National Institute of Health and National Eye Institute. The trial is slated to follow patients undergoing photobiomodulation therapies for up to 1 year. “We have examined the interim data from the Lightsite I study for up to the first 3 months followin...
Source: Mass Device - November 7, 2017 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Optical/Ophthalmic LumiThera Source Type: news

Stem Cell Therapy Among Hot Topics at AAO 2017 Stem Cell Therapy Among Hot Topics at AAO 2017
A potential treatment for two eye conditions that currently have none -- inherited retinal disease and dry age-related macular degeneration -- will be among the most anticipated research presented at AAO 2017.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 3, 2017 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Blindness treatment: Eat THIS £1 food to cut risk of vision loss
VISION loss affects almost two million people in the UK. The leading cause of vision loss is age-related macular degeneration , which currently affects about 600,000 people in the country. (Source: Daily Express - Health)
Source: Daily Express - Health - November 2, 2017 Category: Consumer Health News Source Type: news

Drug giants' legal threat to the NHS for using cheap drugs
Novartis and Bayer made the threat against 12 health boards in Cumbria and North-East England which have advised doctors to use a different treatment for age-related macular degeneration. (Source: the Mail online | Health)
Source: the Mail online | Health - November 1, 2017 Category: Consumer Health News Source Type: news

LumiThera Closes Series B Round of Financing
SEATTLE, Oct. 31, 2017 -- (Healthcare Sales & Marketing Network) -- LumiThera Inc., a clinical stage private medical device company creating a non-invasive photobiomodulation (PBM) treatment for ocular disorders and diseases, today announced it has comple... Devices, Ophthalmology, Venture Capital, Personnel LumiThera, photobiomodulation, Age-related Macular Degeneration, dry AMD (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 31, 2017 Category: Pharmaceuticals Source Type: news

LumiThera raises $6m in Series B
LumiThera said today it raised $5.5 million in a Series B round of financing to support the development of its LT-300 device designed for treating dry age-related macular degeneration. Proceeds from the round will support pursuit of regulatory clearance for the LT-300 device outside the US, including CE Mark approval in the European Union and additional clinical and commercial activities, the Seattle-based company said. “We are pleased with the investor interest in the company and have oversubscribed the Series B round. This is an exciting time for the company and the infusion of new capital will allow us to exe...
Source: Mass Device - October 31, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News LumiThera Source Type: news

MassDevice.com +5 | The top 5 medtech stories for October 19, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. This surgical glue seals wounds in 60 seconds A potentially life-saving surgical glue that is highly elastic and adhesive can quickly seal wounds in seconds without the need for common staples or sutures. The surgical glue, cal...
Source: Mass Device - October 19, 2017 Category: Medical Devices Authors: MassDevice Tags: News Well Plus 5 Source Type: news

Pixium Vision wins French approval for Prima sub-retinal implant study
Pixium Vision (EPA:PIX) said today it won approval from France’s regulatory agency to launch a feasibility clinical study of its next-gen Prima sub-retinal implant in patients with advanced dry age-related macular degeneration. The Prima system is a next-gen wireless implant with a micro photovoltaic chip designed to be implanted under the retina to convert pulsed near-infra-red invisible light received from external glasses with an integrated mini-camera into electrical signals transmitted to the brain through the optic nerve, the company said. The system is designed to treat retinal dystrophies with a foc...
Source: Mass Device - October 19, 2017 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Optical/Ophthalmic Pixium Vision Source Type: news